Rieke E Alten (Rieke Alten)

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 49

Top Topics

Rheumatoid Arthritis

Top Venues

The Journal of rheumatology

Clinical rheumatology

Nature reviews. Rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Rieke E Alten, Juan Carlos Nieto-Gonzalez, Peggy Jacques, Carlomaurizio Montecucco, Robert Moots, Helga Radner, Harald E Vonkeman, Sebastian Heidenreich, Chiara Whichello, Nicolas Krucien, Katrien Van Beneden
What benefit-risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment. RMD open 10 (1) (2024)
Rieke E Alten, Juan Carlos Nieto-Gonzalez, Peggy Jacques, Carlomaurizio Montecucco, Robert Moots, Helga Radner, Harald E Vonkeman, Sebastian Heidenreich, Chiara Whichello, Nicolas Krucien, Katrien Van Beneden
What benefit-risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment. RMD open 10 (1) (2024)
Peter C Taylor, Arthur Kavanaugh, Peter Nash, Janet E Pope, Georg Pongratz, Bruno Fautrel, Rieke E Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, René Westhovens
Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD open 10 (1) (2024)
Peter C Taylor, Arthur Kavanaugh, Peter Nash, Janet E Pope, Georg Pongratz, Bruno Fautrel, Rieke E Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, René Westhovens
Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD open 10 (1) (2024)
Peter C Taylor, Arthur Kavanaugh, Peter Nash, Janet E Pope, Georg Pongratz, Bruno Fautrel, Rieke E Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, René Westhovens
Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD open 10 (1) (2024)
Rieke E Alten, Juan Carlos Nieto-Gonzalez, Peggy Jacques, Carlomaurizio Montecucco, Robert Moots, Helga Radner, Harald E Vonkeman, Sebastian Heidenreich, Chiara Whichello, Nicolas Krucien, Katrien Van Beneden
What benefit-risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment. RMD open 10 (1) (2024)
Lars Erik Kristensen, Khai Jing Ng, Marcus Ngantcha, Jacques Morel, Ennio Lubrano, William Tillett, Rieke E Alten, Vinod Chandran, Àngels Martinez Ferrer, Baojin Zhu, Dominika Kennedy, Thorsten Holzkämper, Nicola J Gullick, Andris Kronbergs, Walid Fakhouri, Inmaculada de la Torre, Dennis G McGonagle
Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study. RMD open 10 (3) (2024)
Rieke E Alten, Juan Carlos Nieto-Gonzalez, Peggy Jacques, Carlomaurizio Montecucco, Robert Moots, Helga Radner, Harald E Vonkeman, Sebastian Heidenreich, Chiara Whichello, Nicolas Krucien, Katrien Van Beneden
What benefit-risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment. RMD open 10 (1) (2024)
Rieke E Alten, Gerd R Burmester, Marco Matucci-Cerinic, Jean-Hugues Salmon, Andrew Östör, Khai Jing Ng, Jens Gerwien, Liliana Zaremba-Pechmann, Alan J M Brnabic, Bruno Fautrel
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients. Rheumatology and therapy (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Rieke E Alten, Hans-Peter Tony, Bettina Bannert, Hubert Nüßlein, Christiane Rauch, Sean E Connolly, Melanie Chartier, Karissa Lozenski, Roland Hackl, Adrian Forster, Peter Peichl
Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus. Clinical rheumatology (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Rieke E Alten, Max Weinbrecht-Mischkewitz
Maximizing the success of biosimilar implementation. Nature reviews. Rheumatology (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Peter C Taylor, Bruno Fautrel, Yves Piette, Susana Romero-Yuste, Jasper Broen, Martin Welcker, Oliver Howell, Elke Rottier, Monia Zignani, Katrien Van Beneden, Roberto Caporali, Rieke E Alten
Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD open 8 (2) (2022)
Peter C Taylor, Bruno Fautrel, Yves Piette, Susana Romero-Yuste, Jasper Broen, Martin Welcker, Oliver Howell, Elke Rottier, Monia Zignani, Katrien Van Beneden, Roberto Caporali, Rieke E Alten
Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD open 8 (2) (2022)
Peter C Taylor, Bruno Fautrel, Yves Piette, Susana Romero-Yuste, Jasper Broen, Martin Welcker, Oliver Howell, Elke Rottier, Monia Zignani, Katrien Van Beneden, Roberto Caporali, Rieke E Alten
Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD open 8 (2) (2022)
Peter C Taylor, Rieke E Alten, Jose María Álvaro Gracia, Yuko Kaneko, Chad Walls, Amanda Quebe, Bochao Jia, Natalia Bello, Jorge Ross Terres, Roy M Fleischmann
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD open 8 (1) (2022)
Maria Sole Chimenti, Rieke E Alten, Maria Antonietta D'Agostino, Elisa Gremese, Uta Kiltz, Ennio Lubrano, Mireia Moreno Martínez-Losa, Thao Pham, Roberta Ramonda, Francesca Romana Spinelli, Chiara Perella, Laura Andreoli
Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD open 7 (3) (2022)
Peter C Taylor, Bruno Fautrel, Yves Piette, Susana Romero-Yuste, Jasper Broen, Martin Welcker, Oliver Howell, Elke Rottier, Monia Zignani, Katrien Van Beneden, Roberto Caporali, Rieke E Alten
Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD open 8 (2) (2022)
Max Mischkewitz, Rieke E Alten
[This is how we treat rheumatoid nodules in patients with rheumatoid arthritis in remission]. Zeitschrift fur Rheumatologie 81 (7) (2022)
Rieke E Alten, Gerd R Burmester, Marco Matucci-Cerinic, Jean-Hugues Salmon, Pedro Lopez-Romero, Walid Fakhouri, Inmaculada de la Torre, Liliana Zaremba-Pechmann, Thorsten Holzkämper, Bruno Fautrel
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis. Rheumatology and therapy (2022)
P G Conaghan, Rieke E Alten, Atul Deodhar, Emma Sullivan, Stuart Blackburn, Haijun Tian, Kunal Gandhi, Steffen M Jugl, Vibeke Strand
Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. RMD open 6 (2) (2021)
Frank Behrens, Michaela Koehm, Tanja Rossmanith, Rieke E Alten, Martin Aringer, Marina Backhaus, Gerd R Burmester, Eugen Feist, Eva Herrmann, Herbert Kellner, Klaus Krueger, Annette Lehn, Ulf Müller-Ladner, Andrea Rubbert-Roth, Hans-Peter Tony, Siegfried Wassenberg, Harald Burkhardt
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). Rheumatology (Oxford, England) 60 (11) (2021)
Roy M Fleischmann, Daniel F Alvarez, Amy E Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang, Rieke E Alten
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293. RMD open 7 (2) (2021)
Mark C Genovese, Herbert Kellner, Yasumasa Arai, Rafael Muniz, Rieke E Alten
Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. RMD open 6 (1) (2021)
Arthur Kavanaugh, Rene R Westhovens, Kevin L Winthrop, Susan J Lee, YingMeei Tan, Di An, Lei Ye, John S Sundy, Robin Besuyen, Luc Meuleners, Mykola Stanislavchuk, Alberto J Spindler, Maria Greenwald, Rieke E Alten, Mark C Genovese
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. The Journal of rheumatology 48 (8) (2021)
Rieke E Alten, Max Weinbrecht-Mischkewitz
2021 ACR guideline reflects changes in RA treatment. Nature reviews. Rheumatology 17 (9) (2021)
HoUng Kim, Rieke E Alten, J R Fraser Cummings, Silvio Danese, Geert R A M D'Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, Jong Hyuk Lee, James O Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven R A Simoens, René Westhovens, Ji Hoon Jeong, Laurent Peyrin-Biroulet
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. mAbs 13 (1) (2021)
HoUng Kim, Rieke E Alten, Luisa Avedano, Axel U Dignass, Fernando Gomollón, Kay Greveson, Jonas Halfvarson, Peter M Irving, Prof Jørgen Jahnsen, Péter L Lakatos, JongHyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven R A Simoens, René Westhovens, Silvio Danese, Ji Hoon Jeong
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 80 (2) (2020)
Lisa Lindner, Johanna Callhoff, Rieke E Alten, Andreas Krause, Wolfgang Ochs, Angela Zink, Katinka Albrecht
Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007-2017. Rheumatology international 40 (12) (2020)
Rieke E Alten, Colin Markland, Malcolm Boyce, Kazuki Kawakami, Rafael Muniz, Mark C Genovese
Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. International journal of rheumatic diseases 23 (11) (2020)
Mohammed A Omair, Alper Erdogan, Nicole Tietz, Rieke E Alten
Physical and Emotional Burden of Rheumatoid Arthritis in Saudi Arabia: An Exploratory Cross-Sectional Study. Open access rheumatology : research and reviews 12 (2020)
Roberto Felice Caporali, Yannick Allanore, Rieke E Alten, Bernard G Combe, Patrick Durez, Florenzo Iannone, Mike T Nurmohamed, Sang Joon Lee, Taek Sang Kwon, Jean Soo Choi, Gahee Park, Dae Hyun Yoo
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert review of clinical immunology 17 (1) (2020)
László Gulácsi, Zsombor Zrubka, Valentin Brodszky, Fanni Rencz, Rieke E Alten, Zoltán Szekanecz, Márta Péntek
Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. Advances in therapy 36 (3) (2019)
Tim Pickles, Rieke E Alten, Maarten Boers, Vivian P Bykerk, Jared Christensen, Robin Christensen, Hubert van Hoogstraten, Lee S Simon, Lai Shan Tam, Ernest H S Choy
Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. The Journal of rheumatology 46 (10) (2019)
Rieke E Alten, Xavier Mariette, Hanns-Martin Lorenz, Hubert Nüßlein, Mauro Galeazzi, Federico Navarro, Melanie Chartier, Julia Heitzmann, Coralie Poncet, Christiane Rauch, Manuela Le Bars
Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. Clinical rheumatology 38 (5) (2019)
Rieke E Alten, Bogdan Batko, Tomas Hala, Hideto Kameda, Sebastiao C Radominski, Vira Tseluyko, Goran Babic, Carol Cronenberger, Sarah Hackley, Muhammad Rehman, Oliver von Richter, Min Zhang, Stanley Cohen
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. RMD open 5 (1) (2019)
Zsombor Zrubka, László Gulácsi, Valentin Brodszky, Fanni Rencz, Rieke E Alten, Zoltán Szekanecz, Márta Péntek
Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. Expert review of pharmacoeconomics & outcomes research 19 (5) (2019)
Rieke E Alten, Eugen Feist, Hanns-Martin Lorenz, Hubert Nüßlein, Reinhard E Voll, Melanie Chartier, Yedid Elbez, Christiane Rauch
Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries. Clinical rheumatology 38 (11) (2019)
Karine Toupin April, Jennifer L Barton, Liana Fraenkel, Alexa Meara, Linda C Li, Peter Brooks, Maarten P T de Wit, Dawn Stacey, France Légaré, Beverley Shea, Anne Lyddiatt, Cathie Hofstetter, Robin Christensen, Marieke Scholte Voshaar, Maria E Suarez-Almazor, Annelies Boonen, Tanya Meade, Lyn March, Janet Elizabeth Jull, Willemina Campbell, Rieke E Alten, Suvi Karuranga, Esi M Morgan, Ayano Kelly, Jessica Kaufman, Sophie Hill, Lara J Maxwell, Dorcas Beaton, Yasser El-Miedany, Shikha Mittoo, Susan J Bartlett, Jasvinder A Singh, Peter S Tugwell
OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. The Journal of rheumatology 46 (10) (2019)
Rieke E Alten, Harald Burkhardt, Eugen Feist, Klaus Krüger, Juergen Rech, Andrea Rubbert-Roth, Reinhard E Voll, Yedid Elbez, Christiane Rauch
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. Arthritis research & therapy 20 (1) (2018)
Melanie Hagen, Matthias Englbrecht, Judith Haschka, Michaela Reiser, Arnd Kleyer, Axel Hueber, Bernhard Manger, Camille Figueiredo, Jayme Fogagnolo Cobra, Hans-Peter Tony, Stephanie Finzel, Stefan Kleinert, Jörg Wendler, Florian Schuch, Monika Ronneberger, Martin Feuchtenberger, Martin Fleck, Karin Manger, Wolfgang Ochs, Hans-Martin Lorenz, Hubert Nüsslein, Rieke E Alten, Jörg Henes, Klaus Krüger, Georg Schett, Jürgen Rech
Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status. The Journal of rheumatology 46 (5) (2018)
Peter C Taylor, Rieke E Alten, Juan J Gomez-Reino, Roberto Caporali, Philippe Bertin, Emma Sullivan, Robert Wood, James Piercy, Radu Vasilescu, Dean Spurden, Jose Alvir, Miriam Tarallo
Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. RMD open 4 (1) (2018)
Rieke E Alten, Xavier Mariette, Hanns-Martin Lorenz, Mauro Galeazzi, Alain Cantagrel, Hubert G Nüßlein, Melanie Chartier, Yedid Elbez, Christiane Rauch, Manuela Le Bars
Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD open 3 (2) (2017)
Rieke E Alten, Hubert G Nüßlein, Xavier Mariette, Mauro Galeazzi, Hanns-Martin Lorenz, Alain Cantagrel, Melanie Chartier, Coralie Poncet, Christiane Rauch, Manuela Le Bars
Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study. RMD open 3 (1) (2017)
Piet van Riel, Rieke E Alten, Bernard Combe, Diana Abdulganieva, Paola Bousquet, Molly Courtenay, Cinzia Curiale, Antonio Gómez-Centeno, Glenn Haugeberg, Burkhard Leeb, Kari Puolakka, Angelo Ravelli, Bernhard Rintelen, Piercarlo Sarzi-Puttini
Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. RMD open 2 (2) (2016)
Vibeke Strand, Eun Bong Lee, Roy Fleischmann, Rieke E Alten, Tamas Koncz, Samuel H Zwillich, David Gruben, Bethanie Wilkinson, Sriram Krishnaswami, Gene Wallenstein
Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD open 2 (2) (2016)